Results 41 to 50 of about 8,055 (251)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

Frontiers in Endocrinology, 2023
PurposeA systematic review and meta-analysis was conducted to synthesize the available data from clinical trials and assess the safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes (T2D) and obesity.MethodsA ...
Qingyue Zeng, Jiao Xu, Xingyu Mu, Yi Shi, Hong Fan, Shuangqing Li   +5 more
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial

Journal of Diabetes Investigation
Aims/Introduction In the SURPASS J‐mono trial, tirzepatide demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes.
Hanaka Mimura, Tomonori Oura, Rina Chin, Masakazu Takeuchi, Kazuya Fujihara, Hirohito Sone   +5 more
doaj   +1 more source

A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use

Endocrinology, Diabetes & Metabolism Case Reports
Hypercalcemia is a prevalent electrolyte disturbance commonly associated with primary hyperparathyroidism, cancer, or medication adverse effects. Thiazide diuretics reduce urinary calcium excretion, increasing calcium reabsorption and hypercalcemia ...
Basil Nduma, Sai Nikhitha Malapati, Veeranna Vibhuti   +2 more
doaj   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source

Assessing the therapeutic potential of Tirzepatide in modulating inflammatory responses and mitigating acute pancreatitis

Animal Models and Experimental Medicine
Background Acute pancreatitis (AP) is a severe inflammation of the pancreas, marked by elevated enzyme levels, cellular inflammation, and necrosis. Recent studies emphasize the critical role of inflammation in AP progression.
Razan Alawaji, Mohamed S. Abdel‐Bakky, Hussein M. Ali, Miad A. Aljuhani, Abdulaziz Arif A. Alshammari, Hashim K. Kamal, Maamoun M. K. Khoja, Kholoud Alsehemi, Mennatallah A. Korani, Eman S. Said   +9 more
doaj   +1 more source

Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis

Frontiers in Pharmacology
Background: Tirzepatide—a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist—is used to treat type 2 diabetes.
Emiko Otsuka, Emiko Otsuka, Mineaki Kitamura, Mineaki Kitamura, Satoshi Funakoshi, Hiroshi Mukae, Tomoya Nishino   +6 more
doaj   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source